These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. O'Brien CF; Jimenez R; Hauser RA; Factor SA; Burke J; Mandri D; Castro-Gayol JC Mov Disord; 2015 Oct; 30(12):1681-7. PubMed ID: 26346941 [TBL] [Abstract][Full Text] [Related]
25. Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia. Fedorenko OY; Loonen AJ; Lang F; Toshchakova VA; Boyarko EG; Semke AV; Bokhan NA; Govorin NV; Aftanas LI; Ivanova SA Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25548108 [TBL] [Abstract][Full Text] [Related]
26. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Tsai G; Goff DC; Chang RW; Flood J; Baer L; Coyle JT Am J Psychiatry; 1998 Sep; 155(9):1207-13. PubMed ID: 9734544 [TBL] [Abstract][Full Text] [Related]
27. Prevalence of tardive dyskinesia, tardive dystonia, and respiratory dyskinesia among Chinese psychiatric patients in Hong Kong. Chiu H; Shum P; Lau J; Lam L; Lee S Am J Psychiatry; 1992 Aug; 149(8):1081-5. PubMed ID: 1353316 [TBL] [Abstract][Full Text] [Related]
28. Tardive dyskinesia and new antipsychotics. Correll CU; Schenk EM Curr Opin Psychiatry; 2008 Mar; 21(2):151-6. PubMed ID: 18332662 [TBL] [Abstract][Full Text] [Related]
29. [Clinical characteristics of patients with tardive dyskinesias]. Held T; Weber T; Krausz H; Ahle G; Hager B; Alfter D; Schulze T; Knapp M; Maier W; Rietschel M Fortschr Neurol Psychiatr; 2000 Jul; 68(7):321-31. PubMed ID: 10945158 [TBL] [Abstract][Full Text] [Related]
30. [The treatment of psychopathologic disorders associated with tardive dyskinesias]. Lajeunesse C; Villeneuve A Encephale; 1988 Sep; 14 Spec No():241-9. PubMed ID: 3063515 [TBL] [Abstract][Full Text] [Related]
31. Factors in the development of severe forms of tardive dyskinesia. Yassa R; Nair NP; Iskander H; Schwartz G Am J Psychiatry; 1990 Sep; 147(9):1156-63. PubMed ID: 1974745 [TBL] [Abstract][Full Text] [Related]
32. Not all that moves is tardive dyskinesia. Khot V; Wyatt RJ Am J Psychiatry; 1991 May; 148(5):661-6. PubMed ID: 1673323 [TBL] [Abstract][Full Text] [Related]
34. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Woerner MG; Alvir JM; Saltz BL; Lieberman JA; Kane JM Am J Psychiatry; 1998 Nov; 155(11):1521-8. PubMed ID: 9812112 [TBL] [Abstract][Full Text] [Related]
35. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Ganzini L; Casey DE; Hoffman WF; McCall AL Arch Intern Med; 1993 Jun; 153(12):1469-75. PubMed ID: 8512437 [TBL] [Abstract][Full Text] [Related]
37. Relationship of awareness of dyskinesia in schizophrenia to insight into mental illness. Arango C; Adami H; Sherr JD; Thaker GK; Carpenter WT Am J Psychiatry; 1999 Jul; 156(7):1097-9. PubMed ID: 10401460 [TBL] [Abstract][Full Text] [Related]
38. Duloxetine-related tardive dystonia and tardive dyskinesia: a case report. Chen PY; Lin PY; Tien SC; Chang YY; Lee Y Gen Hosp Psychiatry; 2010; 32(6):646.e9-646.e11. PubMed ID: 21112461 [TBL] [Abstract][Full Text] [Related]
39. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs]. Seigneurie AS; Sauvanaud F; Limosin F Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134 [TBL] [Abstract][Full Text] [Related]